Dr. Robert A. Nagourney, MD
Pancreatic Cancer Surgery: Know What You Have Consented To!
However, a new dilemma has arisen; the failure of surgeons to comply with Pancreatic Cancer patient’s wishes to have tissue submitted.
top of page
Cancer Blog
- Dr. Robert Nagourney -
Search
Dr. Robert A. Nagourney, MD
Aug 14, 20233 min read
“New” Immune Therapy Active in Late-Stage Cancer Patients
Here in 2023, we
suddenly discover that TIL cells are highly active against cancer, but it was Steven Rosenberg who first described it.
Dr. Robert A. Nagourney, MD
Jul 24, 20232 min read
Stage 4 Cancer Patient Survivals: The Data Is In and It’s Not Good
There has been talk of improved survival in cancer, most progress has reflected screening, early diagnosis, improved staging, and support.
Dr. Robert A. Nagourney, MD
Jun 26, 20233 min read
Challenging Paradigms: The Management of Rectal Cancer
One noteworthy case was a 78-year-old patient successfully treated without surgery.
Dr. Robert A. Nagourney, MD
Jun 2, 20232 min read
Breakthrough for Young Patients with a Rare Form of Liver Cancer
Extremely rare liver cancer that mostly affects people in their twenties associated with a gene rearrangement, mostly lethal, until now.
Dr. Robert A. Nagourney, MD
May 19, 20233 min read
For Medical Oncology, Déjà Vu All Over Again
Patients are being encouraged to contact the researchers to get biopsies and help take charge of their disease.
Dr. Robert A. Nagourney, MD
May 15, 20234 min read
Nagourney Cancer Institute: 20-year Experience in 10,000 Patients
At the 2023 American Association for Cancer Research meeting in Orlando, we reported results of ex vivo analysis of programmed cell death.
Dr. Robert A. Nagourney, MD
Mar 27, 20232 min read
Benefits of Combining Functional Profiling with Nagourney Cancer Institute's 11,000 Patient Studies
Combining Functional Profiling with Nagourney Cancer Institute's 11,000 patient studies provides personalized cancer treatment plans.
Dr. Robert A. Nagourney, MD
Mar 2, 20233 min read
Cancer Patients Do Not Need to Take No for an Answer
Cancer patients must take charge of their disease. If they are well, regardless of their condition, they should look for options.
Dr. Robert A. Nagourney, MD
Feb 15, 20232 min read
Functional Profiling vs. Functional Medicine: What’s the Difference?
We take a different approach to the treatment of cancer – based on profiling how our patients’ cancerous cells will respond to treatment.
Dr. Robert A. Nagourney, MD
Jan 30, 20233 min read
Treatment for Stage 4 Pancreatic Cancer May Be at Hand
After the recommended treatment, FOLFIRINOX, using his tissue we suggested new classes of drugs that target P53 and MEK/ERK.
Dr. Robert A. Nagourney, MD
Dec 30, 20222 min read
A Year-End Reflection
2022 Reflection. Among our most important accomplishments in 2022 was the installation of a world-class Mass Spectrometry research program.
Dr. Robert A. Nagourney, MD
Nov 29, 20222 min read
Lung Cancer Patients Need More Than a Lungmap to Nowhere
I applaud anything that accelerates clinical development, but once again the focus is almost exclusively genomic.
Dr. Robert A. Nagourney, MD
Nov 2, 20222 min read
Is The Role Of The Oncologist To Add Drugs or Subtract Drugs?
Over time I came to realize that the role of the infectious disease expert was not to add antibiotics but to subtract them.
Dr. Robert A. Nagourney, MD
Oct 17, 20223 min read
Do Rare Tumors Hold The Key To Future Cancer Cures?
Can rare tumors offer the way forward? This optimism comes from the fact that not unlike CML, rare cancers may carry unique insights.
Dr. Robert A. Nagourney, MD
Oct 13, 20222 min read
Fibrolamellar Cancer Foundation Symposium September 29, 2022
Fibrolamellar cancer (FLC) is a rare tumor of adolescents and young adults occurring 1 in 5 million that arises as a large mass in the live
Dr. Robert A. Nagourney, MD
Sep 20, 20222 min read
Do The Mutations That Drive Cancer Actually Affect Immunity?
A study in the journal Oncogene finds that pancreatic cancer may progress as a result of the loss of normal immune response. (source: ...
Dr. Robert A. Nagourney, MD
Aug 29, 20222 min read
IN HER2 (+) BREAST CANCER, THE MOST WIDELY USED TREATMENT MAY NOT BE THE RIGHT ONE FOR YOU
Despite advances in breast cancer management, we must all recognize that every patient is unique and their treatments should be too.
Dr. Robert A. Nagourney, MD
Aug 15, 20223 min read
STAGE IV PANCREATIC CANCER: A GOOD OPTION AFTER FOLFIRINOX?
40-year-old Hispanic female transferred from UCSD after presenting several weeks earlier with widely metastatic Stage IV pancreatic cancer.
Dr. Robert A. Nagourney, MD
Aug 10, 20223 min read
Stage 4 Triple-Negative Breast Cancer: The Right Treatment May Be At Hand.
A famous medical center recommended a treatment widely used for breast cancer, but not necessarily the best one for Stage 4 Triple-Negative.
bottom of page